OncoMatch/Clinical Trials/NCT04038619
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
Is NCT04038619 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Loperamide for colitis.
Treatment: Loperamide — This trial studies how well fecal microbiota transplantation works in treating diarrhea or colitis (inflammation of the intestines) that is caused by certain types of medications (called immune-checkpoint inhibitors) in patients with genitourinary cancer. Fecal microbiota transplantation may effectively reduce the incidence of immune checkpoint inhibitor-induced diarrhea/colitis.
Check if I qualifyExtracted eligibility criteria
Cancer type
Melanoma
Non-Small Cell Lung Carcinoma
Ovarian Cancer
Endometrial Cancer
Breast Carcinoma
Cervical Cancer
Prior therapy
Must have received: checkpoint inhibitor
Treatment with any ICPI agent(s)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify